(Q47986812)

7 February 2018

title

Monoclonal antibodies produced by muscle after plasmid injection and electroporation (English)

1 reference

7 February 2018

1 reference

1 reference

7

Bjarne Bogen

1 reference

7 February 2018

4

Inger Sandlie

1 reference

7 February 2018

Elin Danielsen Lunde

3

object named as

Elin Lunde

1 reference

7 February 2018

author name string

Torunn Elisabeth Tjelle

1

1 reference

7 February 2018

Alexandre Corthay

2

1 reference

7 February 2018

Terje E Michaelsen

5

1 reference

7 February 2018

Iacob Mathiesen

6

1 reference

7 February 2018

publication date

1 March 2004

1 reference

7 February 2018

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Molecular Therapy

1 reference

7 February 2018

volume

9

1 reference

7 February 2018

issue

3

1 reference

7 February 2018

page(s)

328-336

1 reference

7 February 2018

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

1 reference

Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Sustained Systemic Delivery of Monoclonal Antibodies by Genetically Modified Skin Fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Skin as a potential organ for ectopic monoclonal antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

High In Vivo Production of a Model Monoclonal Antibody on Adenoviral Gene Transfer

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Complement activation by recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Gene therapy. Safer and virus-free?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Gene therapy. What to do when clear success comes with an unclear risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Gene transfer into muscle by electroporation in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

High-efficiency gene transfer into skeletal muscle mediated by electric pulses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Activation of mouse complement by monoclonal mouse antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

DNA immunization induces protective immunity against B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Localization of murine Ig-1b and Ig-1a (IgG 2a) allotypic determinants detected with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2003.12.007

1 reference

7 February 2018

1 reference

7 February 2018